The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3
作者：
Shafiq, Aimen [1 ]
Mahboob, Eman [1 ]
Samad, Muhammad Ammar [1 ]
Rehman, Mohammad Hassam Ur [1 ]
Tharwani, Zoaib Habib [1 ]
机构：
[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan
来源：
ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷
关键词：
Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;
D O I：
10.1016/j.amsu.2022.104555
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Physical exercise for obesity and T2DM mitigation in polycystic ovary syndrome: the role of adipose tissue
    Santos, Matheus Pedro
    Azevedo-Martins, Anna Karenina
    Rodrigues, Anderson Oliveira
    Aquino, Nayara S. S.
    Evangelista, Fabiana S.
    METABOLISM AND TARGET ORGAN DAMAGE, 2025, 5 (01):
  • [42] The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
    Delanaye, Pierre
    Scheen, Andre J.
    DIABETES & METABOLISM, 2021, 47 (06)
  • [43] New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family
    El Khayari, Abdellatif
    Hakam, Soukaina Miya
    Malka, Gabriel
    Rochette, Luc
    El Fatimy, Rachid
    GENES & DISEASES, 2024, 11 (06)
  • [44] Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
    Ito, Hiroyuki
    Matsumoto, Suzuko
    Izutsu, Takuma
    Kusano, Eiji
    Nishio, Shinya
    Antoku, Shinichi
    Yamasaki, Tomoko
    Mori, Toshiko
    Togane, Michiko
    Ando, Shigenori
    Tsugami, Emiko
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 1783 - 1794
  • [45] Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
    Aronson, Ronnie
    Frias, Juan
    Goldman, Allison
    Darekar, Amanda
    Lauring, Brett
    Terra, Steven G.
    DIABETES OBESITY & METABOLISM, 2018, 20 (06) : 1453 - 1460
  • [46] Serum Pentosidine is Associated with Cardiac Dysfunction and Atherosclerosis in T2DM
    Cao, Yuyan
    Ye, Xinhua
    Yuan, Xiaoqing
    Liu, Juan
    Zhang, Qing
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 237 - 244
  • [47] Disrupted resting-state attentional networks in T2DM patients
    Xia, Wenqing
    Wang, Shaohua
    Rao, Hengyi
    Spaeth, Andrea M.
    Wang, Pin
    Yang, Yue
    Huang, Rong
    Cai, Rongrong
    Sun, Haixia
    SCIENTIFIC REPORTS, 2015, 5
  • [48] A Review of micro RNAs changes in T2DM in animals and humans
    Afsharmanesh, Mohammad Reza
    Mohammadi, Zeinab
    Mansourian, Azad Reza
    Jafari, Seyyed Mehdi
    JOURNAL OF DIABETES, 2023, 15 (08) : 649 - 664
  • [49] Personalized medicine- future of diagnosis and management of T2DM
    Verma, Sushma
    Rizvi, Saliha
    Abbas, Mohd
    Raza, Tasleem
    Mahdi, Farzana
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (04) : 2425 - 2430
  • [50] Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients
    Liu, Xiaojie
    Mei, Tao
    Chen, Wei
    Ye, Shandong
    MEDIATORS OF INFLAMMATION, 2017, 2017
12345